Mylan NV's plan to invest in complex generics and biosimilars is about to begin paying dividends, helping ease the company through the challenging US commercial market for small molecule generic drugs, at least that was the message management, including CEO Heather Bresch and President Rajiv Malik, tried to deliver to investors during the company's third quarter earnings call Nov. 6.
The company is hoping to ride the positive momentum coming off the FDA approval of a generic version of








